Drug for the treatment of mastitis in cows

 

(57) Abstract:

The invention relates to veterinary medicine, in particular drugs for the treatment of mastitis in cattle. The product contains ammonia, dimexide, the BMF from the production of oil from pumpkin seeds and the media type Aerosil-380 in the following ratio, wt.%: 30% solution of Dimexidum 4 - 5; 0.5% solution of ammonia) 2 - 4; the carrier of Aerosil-380 2 - 5; BMF - the rest. The drug allows to simplify its use and to improve therapeutic efficacy. table 1.

The invention relates to veterinary medicine, in particular drugs for the treatment of mastitis in cattle.

Mastitis is one of the causes of infertility in cows. Disease of cows mastitis in the previous lactation affects prenatal development of the fetus and clinical-physiological status of newborn calves, resulting in reduced milk production, poor quality of milk and a high percentage of culling cows.

Known drugs for the treatment of mastitis on the basis of antibiotics, sulfonamides, nitrofuranov [1].

The disadvantage of using these drugs is the emergence of resistant races of mcast drugs delays the development of lactic acid bacteria, negative impact on milk enzymes involved in the technological processes of manufacture of cheese and fermented milk products. Closest to the present invention is a drug for the treatment of mastitis in cows "Vivaton" containing plant-based - broth of herbs and ammonia [2] . Lack of preparation is the complexity of its application - processing up to 3 times a day with the obligatory massage for 10 minutes, in terms of livestock farms leads to higher costs of labour and veterinary workers. In addition, the drug has a relatively low efficiency.

The technical result is to simplify use and increase therapeutic efficacy. This is achieved by the fact that the product contains ammonia and anti-inflammatory agent dimexide [3] , the BMF (obtained in the production of oil from pumpkin seeds), carrier (excipient for uniform distribution of the drug Aerosil-380) in the following ratio of initial components, wt.%:

30% solution of Dimexidum - 4 - 5

a 0.5% solution of ammonia) - 2 - 4

Media Aerosil-380 - 2 - 5

The BMF - Rest

Part of the BMF common term in the production of pumpkin oil) includes tocoferol the economic efficiency is achieved due to the joint action of the components, part of the preparation. The basis of liniment, which prepared the drug, provides an easy and rapid penetration of substances through the skin and the achievement of inflammation. In addition, lipophilic vitamins inside the droplets of the emulsion are protected thus advanced from destruction by oxygen.

The drug is prepared as follows.

To prepare 10 kg of the drug in the mixer make (example 1) 400 g of a 30% aqueous solution of Dimexidum, 200 g of 0.5% aqueous ammonia solution, 0.5 kg of BMF and mix. Then make the rest of the BMF (8,7 kg) and all mix until smooth. To obtain 2% of the form of liniment in the resulting composition, make 200 g Aerosila-380 and thoroughly mixed in the mixer.

Preparation on physical properties is a mass of green color with a specific smell, is stable in a cool dark place for 6 months.

To treat drug should be 1 time per day. Immediately after milking machine manually by leftover milk from sick and healthy lobes. Then apply to the udder preparation.

When subclinical mastitis of drug administered twice on the course Leche is t from the bottom up. In catarrhal from top to bottom, the duration of treatment 3 days. In examples 1-3 lists the specific formulations of the drug, wt.%.

Example 1.

30% solution of Dimexidum - 4

0.5% ammonia solution - 2

Aerosil-380 - 2

The BMF - Rest

Example 2.

30% solution of Dimexidum - 4

0.5% ammonia solution - 3

Aerosil-380 - 3

The BMF - Rest

Example 3.

30% solution of Dimexidum - 5

0.5% ammonia solution - 4

Aerosil-380 - 5

The BMF - Rest

Clinical testing of the proposed drug conducted on lactating cows in the amount of 89 goals, which were divided into groups according to the forms of the disease mastitis. The results of the comparative effectiveness of known and proposed product in the various forms of mastitis in the table.

The data show that a higher therapeutic effect of the proposed drug has in catarrhal mastitis (recovery of 100% of cows), although it was administered three times in the course of treatment versus 12 treatments of known drug.

therapeutic efficacy of the specified drug is also higher in subclinical (90,9%) and serous (90%) of mastitis in comparison with the known ratio is to increase the effectiveness of treatment measures in mastitis cows and simplify its use.

Sources of information

1. Heidrich H.-D., Gruner I. Diseases of cattle. - M.: Agropromizdat, 1985, S. 154.

2. Deryabin, A. M., Usha B. C., The Latter A. G., Taller.G. Veterinary medicine, 1991, No. 1, S. 50.

3. Mashkovsky M. A. Medicines. - M.: Medicine, 1993, S. 222 and 223.

Drug for the treatment of mastitis in cows that contains plant-based and ammonia, characterized in that it further comprises dimexide, and as a vegetable basis - BMF obtained in the production of oil from pumpkin seeds, and media type Aerosil-380 in the following ratio of initial components, wt.%:

30% Solution of Dimexidum - 4 - 5

a 0.5% Solution of ammonia) - 2 - 4

Media Aerosil-380 - 2 - 5

The BMF - Rest

 

Same patents:
The invention relates to medicine, in particular to obstetrics, and for measures aimed at improving the reproductive health of the population
The invention relates to medicine, in particular for secondary prevention post-radiation impaired spermatogenesis, and can be used in medical and health institutions
The invention relates to the field of medicine

The invention relates to new naphtylpropionate F.-ly (I), where R1and R2- N, -HE or-O(C1-C4-alkyl); R3- 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholinyl, dialkylamino - or 1-hexamethylen-aminogroup; n = 2 or 3, or pharmaceutically acceptable salts

The invention relates to medicine, namely to andrology, reproductive science

The invention relates to new niftystories compounds of formula I, where R1and R2- H, -OH, -O(C1-C4alkyl), -OCOC6H5, -OCO(C1-C6alkyl), -OSO2(C4-C6alkyl); R3- 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, 1 hexamethyleneimino; intermediate compounds, which are suitable for easing symptoms of postmenopausal syndrome, including osteoporosis, hyperlipemia and estrogenzawisimy cancer, and inhibition of uterine fibroids, endometriosis and proliferation of aortic smooth muscle cells

The invention relates to the field of medicine and relates to a pharmaceutical combination preparation for hormonal contraception

The invention relates to the field of medicine and relates to a pharmaceutical combination preparation of the two, Packed in spatial terms separately in the same packaging unit, intended for oral administration at a time sequentially hormonal components, which consist, depending on the circumstances, placed in spatial terms separately in one packing unit and retrieved separately daily dosing units, and the first hormonal component as hormonal biologically active substance contains a combination of estrogen and at least sufficient to suppress ovulation dosage gestagenna the drug either in-phase or multi-phase execution, and the second hormonal component as hormonal biologically active substance contains only one estrogen drug, and the first hormonal component covers 23 or 25, and the second hormonal component covers 4-10 daily dosing units, daily dosage units of the first hormonal component does not contain a combination of biogenic estrogen and synthetic estrogen, and the total number of daily dosing
The invention relates to medicine, in particular to the gynecologist, and for the treatment of oligomenorrhea in adolescent girls

The invention relates to the oil industry and can be used as a food product, as well as pharmacological tools

Drops heart // 2169577
The invention relates to pharmaceutical industry and can be used for the treatment of patients with cardiovascular disease (CLO), cardiac tachyarrhythmias, angina pectoris, arterial hypertension
The invention relates to medicine and can be used in therapy and cardiology
The invention relates to medicine, namely to create a plant that can be used for the treatment and prevention of aging

The invention relates to veterinary science and medicine, in particular for the production and use of medicines for the prevention and treatment of radiation injuries, achieved by increasing the specific resistance of the organism

The invention relates to medicine, namely to the chemical-pharmaceutical industry

The invention relates to medicine
The invention relates to medicine
Up!